Avalon BioVentures
Overview
Avalon BioVentures is a venture capital firm focused on building and funding early-stage life science and biomedical companies. It emerged from Avalon Ventures as a life-science-only fund and utilizes its own accelerator to support portfolio companies in developing breakthrough therapies.
Portfolio Companies
7
Website
avalonbioventures.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Valora Therapeutics Inc. | Nov 2024 | Seed | Lead |
| AeroRx Therapeutics | Oct 2025 | Series A | Lead |
| Arialys Therapeutics | Sep 2023 | Seed | Lead |
| Enlaza Therapeutics | Apr 2024 | Series A | - |
| Fortis Therapeutics | Mar 2021 | Series A Extension | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Avalon BioVentures based?
Avalon BioVentures is headquartered in La Jolla, California, United States.
When was Avalon BioVentures founded?
Founding year information for Avalon BioVentures is not publicly available.
How many portfolio companies does Avalon BioVentures have?
Avalon BioVentures has 7 portfolio companies in Caplight's dataset.
What are some companies in Avalon BioVentures's portfolio?
Portfolio companies visible on Caplight include Valora Therapeutics Inc., AeroRx Therapeutics, Arialys Therapeutics, Enlaza Therapeutics, Fortis Therapeutics.
What was Avalon BioVentures's most recent investment shown here?
Avalon BioVentures's most recent investment in this portfolio sample was in AeroRx Therapeutics in 2025.
What sectors does Avalon BioVentures focus on?
Avalon BioVentures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Avalon BioVentures focus on?
Avalon BioVentures typically invests at the Early stage.
What is Avalon BioVentures's AUM?
Avalon BioVentures's assets under management are estimated between $135.0M and $135.0M.